BioCryst Pharmaceuticals, Inc. (BCRX)

BioCryst Pharmaceuticals, Inc. is trading at $8.47, down 0.59% on the session. The 50 day average sits at $8.63 and the 200 day at $8.75, which puts the stock in a downtrend. RSI is at 54.8, which reads as neutral, and MACD is bullish crossover. Volume is below average.

The nearest support is around $8.02 with resistance near $8.60, so that band frames the current range. Average daily movement is roughly $0.31, or about 3.6% of the share price, which is what any stop placement has to allow for. The overall health score of 41 out of 100 combines a trend score of 7, momentum of 69 and a risk score of 58.

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.